Norman Ng, Director, Patient Advocacy and Public Affairs at Healthcare Thinkers, shared on LinkedIn:
“A New Treatment Opportunity for ES-SCLC Patients in Hong Kong
As the Convenor of the Lung Cancer Patient Concern Group, I sincerely thank the Greater China Cancer Foundation and CHIATAI TIANQING Pharmaceutical Group for launching a compassionate Named Patient Program (NPP)** that brings hope to patients with extensive-stage small cell lung cancer (ES-SCLC).
Program Details
- Free access to medication for up to 20 eligible patients
- Continued free treatment even after drug registration, until disease progression or clinical ineligibility
- Application through treating physician; DKSH will coordinate drug supply
Our Message to Patients
If you or someone you know is facing ES-SCLC, please speak to your oncologist about this opportunity. This program is more than treatment – it’s a lifeline.
Let’s spread the word and bring hope to those who need it most.”
More insights featuring Norman Ng.
